These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34193698)

  • 1. [Analysis of contractile functions of human iPS-derived cardiomyocytes using motion field imaging].
    Yamaguchi M; Sakamoto K; Kurokawa J
    Nihon Yakurigaku Zasshi; 2021; 156(4):214-219. PubMed ID: 34193698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continued exposure of anti-cancer drugs to human iPS cell-derived cardiomyocytes can unmask their cardiotoxic effects.
    Sakamoto K; Sakatoku K; Sugimoto S; Iwasaki N; Sano Y; Yamaguchi M; Kurokawa J
    J Pharmacol Sci; 2019 Aug; 140(4):345-349. PubMed ID: 31521491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
    Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
    Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic cardiotoxicity assessment of BMS-986094, a guanosine nucleotide analogue, using human iPS cell-derived cardiomyocytes.
    Yanagida S; Satsuka A; Hayashi S; Ono A; Kanda Y
    J Toxicol Sci; 2021; 46(8):359-369. PubMed ID: 34334557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
    Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
    Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.
    Cui N; Wu F; Lu WJ; Bai R; Ke B; Liu T; Li L; Lan F; Cui M
    J Cell Mol Med; 2019 Jul; 23(7):4627-4639. PubMed ID: 31106979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide CRISPR/Cas9 screening in human iPS derived cardiomyocytes uncovers novel mediators of doxorubicin cardiotoxicity.
    Sapp V; Aguirre A; Mainkar G; Ding J; Adler E; Liao R; Sharma S; Jain M
    Sci Rep; 2021 Jul; 11(1):13866. PubMed ID: 34230586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes.
    Zhao L; Zhang B
    Sci Rep; 2017 Mar; 7():44735. PubMed ID: 28300219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manipulation-free cultures of human iPSC-derived cardiomyocytes offer a novel screening method for cardiotoxicity.
    Rajasingh S; Isai DG; Samanta S; Zhou ZG; Dawn B; Kinsey WH; Czirok A; Rajasingh J
    Acta Pharmacol Sin; 2018 Oct; 39(10):1590-1603. PubMed ID: 29620051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes.
    Kurokawa YK; Shang MR; Yin RT; George SC
    Toxicol Lett; 2018 Mar; 285():74-80. PubMed ID: 29305325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
    Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
    Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated image analysis system for studying cardiotoxicity in human pluripotent stem cell-Derived cardiomyocytes.
    Cao L; der Meer ADV; Verbeek FJ; Passier R
    BMC Bioinformatics; 2020 May; 21(1):187. PubMed ID: 32408861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying drug-induced structural toxicity in hepatocytes and cardiomyocytes derived from hiPSCs using a deep learning method.
    Maddah M; Mandegar MA; Dame K; Grafton F; Loewke K; Ribeiro AJS
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106895. PubMed ID: 32629158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
    Satsuka A; Kanda Y
    Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of dual-cardiotoxicity evaluation method based on analysis of field potential and contractile force of human iPSC-derived cardiomyocytes / multielectrode assay platform.
    Lee SG; Kim J; Oh MS; Ryu B; Kang KR; Baek J; Lee JM; Choi SO; Kim CY; Chung HM
    Biochem Biophys Res Commun; 2021 May; 555():67-73. PubMed ID: 33813278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An efficient human stem cells derived cardiotoxicity testing platform for testing oncotherapeutic analogues of quercetin and cinnamic acid.
    Mandal S; Gamit N; Biswas S; Rao CM; Sethi G; Warrier S
    Sci Rep; 2022 Dec; 12(1):21362. PubMed ID: 36494370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes.
    Maillet A; Tan K; Chai X; Sadananda SN; Mehta A; Ooi J; Hayden MR; Pouladi MA; Ghosh S; Shim W; Brunham LR
    Sci Rep; 2016 May; 6():25333. PubMed ID: 27142468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs.
    Sachinidis A
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.